𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin

✍ Scribed by Lorraine Baltzer Cleri; Mark G. Kris; Leslie B. Tyson; Katherine M. W. Pisters; Rebecca A. Clark; Richard J. Gralla

Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
526 KB
Volume
76
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

The addition of cisplatin to cyclophosph
The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients
✍ Thierry Urban; Claude Chastang; FranΓ§ois-Xavier Lebas; Jean-Paul Duhamel; Guy Ad πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

A phase II trial of oral tegafur and ura
A phase II trial of oral tegafur and uracil plus cisplatin in patients with inoperable nonsmall cell lung cancer
✍ Yukito Ichinose; Nobuko Takanashi; Tokujiro Yano; Hiroshi Asoh; Hideki Yokoyama; πŸ“‚ Article πŸ“… 1995 πŸ› John Wiley and Sons 🌐 English βš– 391 KB πŸ‘ 2 views

## Background: The combination of uracil and tegafur in a 4:1 molar concentration (uft) has a greater antitumor activity than 5-fluorouracil (5-fu) and tegafur. because the combination of 5-fu and cisplatin has been proven to have a synergistic antitumor effect in many experimental and clinical stu

Alternated approach with local irradiati
Alternated approach with local irradiation and combination chemotherapy including cisplatin or carboplatin plus epirubicin and etoposide in intermediate stage non-small cell lung cancer
✍ Pasquale Cornella; Gianfranco Scoppa; Antonio Daponte; Gennaro Musefta; Caterina πŸ“‚ Article πŸ“… 1994 πŸ› John Wiley and Sons 🌐 English βš– 752 KB

Background. Prognosis of unresectable non-small cell lung cancer (NSCLC) patients is disappointing: their median survival time does not exceed 8-12 months. Recently, some authors reported an increased response rate and sometimes a prolonged survival for patients with intrathoracic disease treated wi